Lhasa and Optibrium enter research and product development collaboration
Drug discovery software specialists combine expertise to extend studies into drug metabolism modelling.
Optibrium and Lhasa have formed a collaborative partnership to research next-generation drug metabolism modelling. Results from the work will be used by both organisations in the development of future products with improved and extended metabolism prediction capabilities.
The development of methods to predict metabolism is an important avenue of research and finds application in the development of drugs, cosmetics, nutritional supplements and agrochemicals. It is necessary to understand a compound’s pharmacokinetics and ensure that it has sufficient exposure at a target to exert its therapeutic effect. In addition to this, it is important to predict the formation of toxic metabolites, which contributes to the high attrition rates experienced in the development of new chemical entities, the imposition of black-box warnings or even the withdrawal of approved pharmaceuticals. Therefore, the ability to identify potential metabolite issues early is of crucial importance to improving the efficiency and safety of the drug discovery process.
The research project has appointed Dr Mario Öeren as Senior Scientist to lead the study and work with a team of scientists from both Lhasa and Optibrium. As a theoretical chemist who has specialised into computational chemistry, Mario has a PhD in Natural Sciences from Tallinn University of Technology, Estonia where he has since worked as a researcher and lecturer. Mario will be based at Optibrium’s headquarters in Cambridge, UK.
Dr Matt Segall, CEO at Optibrium said: “This R&D collaboration with Lhasa builds on a long-standing relationship and is part of our continued investment in the development of novel technologies to improve efficiency in drug discovery. We welcome Mario to the team and look forward to extending the metabolism modelling capabilities within our combined product portfolio for the mutual benefit of Lhasa members and StarDrop users.”
Dr Chris Barber, Director of Science at Lhasa added: “We are excited by the complementary approaches that Lhasa and Optibrium have applied in the past with Lhasa capitalising on data donated by its member organisations and Optibrium applying theoretical approaches. Both approaches have their advantages but combining and applying them across all stages of development should allow us to provide real benefit to the end user.”
In StarDrop, Optibrium has developed a comprehensive suite of integrated software with a highly visual and user-friendly interface. It enables a seamless flow from the latest data through to predictive modelling and decision making regarding the next round of synthesis and research, improving the speed, efficiency and productivity of the drug discovery process. Seamlessly connecting with other models, informatics methods and databases, StarDrop provides user-friendly access to resources making project management quicker and simpler.
Lhasa specialises in the development of transparent in silico models together with supporting databases in the fields of toxicology, metabolism, degradation and organic synthesis. The company is considered a pioneer in the production of knowledge-based systems and Meteor Nexus, the expert knowledge-based system for the prediction of metabolism, is used extensively within the pharmaceutical and related industries.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance